Sign in
SCYX Stock Price, Chart, Stats & News
SCYNEXIS, Inc.
Save
23.90M
Market cap
–
Current P/E
3.72x
Forward P/E
SCYX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -77.93% |
Pretax margin | -41.79% |
Net margin | -41.79% |
Effective tax rate | – |
ROA | -14.58% |
ROE | -19.05% |
D/E | 0.04x |
Interest coverage ratio | -33.10x |
SCYX valuation
P/E | – |
P/S | 1.76x |
P/B | 0.72x |
P/CF | -6.70x |
P/FCF | -6.87x |
P/OCF | -6.70x |
PEG | -0.06x |
EV multiple | 3.38x |
About
SCYNEXIS, Inc. is a biotechnology firm based in the U. S. dedicated to developing therapies for fungal infections. The company's flagship product, BREXAFEMME (ibrexafungerp tablets), has received approval for the treatment of vulvovaginal candidiasis (VVC).
Similar securities
Based on sector and market capitalization
Report issue